Mankind Pharma Q4 PAT rises by Rs 30

Delhi-based pharma major Mankind Pharma reported 30.4 per cent year-on-year (YoY) growth in consolidated net profit for the March quarter (Q4) of FY26 due to strong domestic demand for legacy drugs used to treat long-term diseases.

The drugmaker reported a profit after tax (PAT) of Rs 559 crore, up from Rs 429 crore in the same quarter last year. Its revenue from operations also increased by 11.8 per cent year-on-year to Rs 3,443 crore from Rs 3,079 crore in Q4FY25.

Commenting on the numbers, Rajeev Juneja, Vice Chairman and Managing Director, Mannkind Pharma, said the company’s earnings growth was driven by performance in domestic markets and growth in the specialty portfolio of Bharat Serum and Vaccine (BSV).

MannKind’s domestic segment, which contributes 85 per cent to its total revenue, grew 13.4 per cent to Rs 2,886 crore in the March quarter. Domestic growth was led by strong demand for drugs in older therapeutics such as cardiovascular and anti-diabetes.

Juneja said Mankind’s chronic share grew 120 basis points (bps) year-on-year to nearly 40 per cent in Q4FY26. “This was driven by strong growth of 14.7 per cent in the cardiac and 11.6 per cent growth in the anti-diabetes segment,” he said.

The drugmaker reported 20 per cent year-on-year growth in its over-the-counter (OTC) consumer healthcare business, driven by healthy growth in sales of brands such as Manforce, Prega News, Gas-O-Fast and Nimulid.

However, international revenues witnessed a slower growth of 4 per cent year-on-year due to the impact of geopolitical headwinds.

“Excluding BSV, MannKind launches four new products in FY2026, taking the total number of launched products in the US to 48,” the company said in a statement to the stock exchanges.

Mankind Pharma announced its results after the market closed. The stock closed 0.09 per cent lower at Rs 2,494.1 per share on the Bombay Stock Exchange (BSE) on Tuesday.